Proteinuria is a condition in which abnormal protein levels are found in urine.
Programs + Services
The Tufts MC Kidney and Blood Pressure Center provides both one-time consultations and ongoing care for chronic or acute kidney disease and high blood pressure.
More information about programs and services
Research + Clinical Trials
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome.
The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year.
More information about research and clinical trials
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine.
The study is comprised of an optional pre-screening period, a screening period, a treatment period and a follow-up period. If you qualify, you will receive either the study drug Atrasenten or placebo for up to 2.5 years.
More information about research and clinical trials
The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
More information about research and clinical trials
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More information about research and clinical trials
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
More information about research and clinical trials
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More information about research and clinical trials
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More information about research and clinical trials
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More information about research and clinical trials
